Search

Displaying results 1571 - 1580 of 2437 in total
  1. Drug

    Sarafloxacin

    go.drugbank.com/drugs/DB11491
    ApprovedVet approvedWithdrawn

    Sarafloxacin is a quinolone antibiotic drug, which was discontinued by its manufacturer, Abbott Laboratories, before receiving approval for use in the US or Canada.

    Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme Inhibitors
  2. Drug

    Difloxacin

    go.drugbank.com/drugs/DB11511
    ExperimentalVet approved

    Difloxacin is a synthetic fluoroquinolone used in veterinary. As an antibacterial, it presents a broad bactericidal spectrum and its effects are dependent on its concentration. However, it presents a reduced efficacy when compared to oth...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 Substrates
  3. Drug

    Salinomycin

    go.drugbank.com/drugs/DB11544
    ExperimentalVet approved

    Categories: P-glycoprotein inhibitors
  4. Drug

    Lesinurad

    go.drugbank.com/drugs/DB11560
    ApprovedWithdrawn

    Lesinurad is an oral uric acid transporter 1 (URAT1) inhibitor indicated for the treatment of hyperuricemia associated with gout. It reduces serum uric acid concentration through the inhibition of URAT1, an enzyme responsible for reuptak...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inducers
  5. Drug

    Insulin tregopil

    go.drugbank.com/drugs/DB11568
    Investigational

    Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 Enzyme Inducers
  6. Drug

    Elbasvir

    go.drugbank.com/drugs/DB11574
    Approved

    Elbasvir is a direct-acting antiviral medication used as part of combination therapy to treat chronic hepatitis C, an infectious liver disease caused by infection with hepatitis C virus (HCV). HCV is a single-stranded RNA virus that is c...

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  7. Drug

    Lifitegrast

    go.drugbank.com/drugs/DB11611
    ApprovedInvestigational

    Lifitegrast is a FDA approved drug for the treatment of keratoconjunctivitis sicca (dry eye syndrome). It is a tetrahydroisoquinoline derivative and lymphocyte function-associated antigen-1 ( LFA-1) antagonist that was discovered through...

    Categories: Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 Enzyme Inhibitors
  8. Drug

    Rupatadine

    go.drugbank.com/drugs/DB11614
    ApprovedInvestigational

    Rupatadine is a dual histamine H1 receptor and platelet activating factor receptor antagonist that is used for symptomatic relief in seasonal and perennial rhinitis as well as chronic spontaneous urticaria. It was approved for marketing ...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 Substrates
  9. Drug

    Tucatinib

    go.drugbank.com/drugs/DB11652
    ApprovedInvestigational

    Tucatinib is a kinase inhibitor drug used with trastuzumab and capecitabine in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tuca...

    Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitors
  10. Drug

    Treosulfan

    go.drugbank.com/drugs/DB11678
    ApprovedInvestigational

    Treosulfan is a prodrug alternative to busulfan for myeloablative conditioning prior to hematopoietic stem cell transplantation. It was approved by the EMA in June 2019 and by the FDA in January 2025 for use in combination with fludarabine.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inhibitors